142 related articles for article (PubMed ID: 21385928)
21. Natural history of human aberrant crypt foci and correlation with risk factors for colorectal cancer.
Ohkubo H; Takahashi H; Yamada E; Sakai E; Higurashi T; Uchiyama T; Hosono K; Endo H; Taguri M; Nakajima A
Oncol Rep; 2012 May; 27(5):1475-80. PubMed ID: 22246586
[TBL] [Abstract][Full Text] [Related]
22. Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp.
Matsuhashi N; Nakajima A; Shinohara K; Oka T; Yazaki Y
Am J Gastroenterol; 1998 Nov; 93(11):2261-6. PubMed ID: 9820411
[TBL] [Abstract][Full Text] [Related]
23. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans.
Rudolph RE; Dominitz JA; Lampe JW; Levy L; Qu P; Li SS; Lampe PD; Bronner MP; Potter JD
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):605-8. PubMed ID: 15767337
[TBL] [Abstract][Full Text] [Related]
25. Genetic and epigenetic changes in aberrant crypt foci and serrated polyps.
Suehiro Y; Hinoda Y
Cancer Sci; 2008 Jun; 99(6):1071-6. PubMed ID: 18384435
[TBL] [Abstract][Full Text] [Related]
26. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
27. Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm.
Sakai E; Takahashi H; Kato S; Uchiyama T; Hosono K; Endo H; Maeda S; Yoneda M; Taguri M; Nakajima A
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1918-24. PubMed ID: 21750169
[TBL] [Abstract][Full Text] [Related]
28. BRAF mutations in aberrant crypt foci and hyperplastic polyposis.
Beach R; Chan AO; Wu TT; White JA; Morris JS; Lunagomez S; Broaddus RR; Issa JP; Hamilton SR; Rashid A
Am J Pathol; 2005 Apr; 166(4):1069-75. PubMed ID: 15793287
[TBL] [Abstract][Full Text] [Related]
29. Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas.
DuBois RN
Gastroenterology; 1995 Apr; 108(4):1310-4. PubMed ID: 7698600
[TBL] [Abstract][Full Text] [Related]
30. RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis.
Subramaniam MM; Chan JY; Soong R; Ito K; Yeoh KG; Wong R; Guenther T; Will O; Chen CL; Kumarasinghe MP; Ito Y; Salto-Tellez M
Am J Gastroenterol; 2009 Feb; 104(2):426-36. PubMed ID: 19174785
[TBL] [Abstract][Full Text] [Related]
31. Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse.
Song J; Medline A; Mason JB; Gallinger S; Kim YI
Cancer Res; 2000 Oct; 60(19):5434-40. PubMed ID: 11034085
[TBL] [Abstract][Full Text] [Related]
32. Oncoprotein coexpression in human aberrant crypt foci and minute polypoid lesions of the large bowel.
Shpitz B; Bomstein Y; Shalev M; Liverant S; Kaufman Z; Klein E; Mekori Y; Bernheim J
Anticancer Res; 1999; 19(4B):3361-6. PubMed ID: 10652634
[TBL] [Abstract][Full Text] [Related]
33. Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci.
Kim KP; Whitehead C; Piazza G; Wargovich MJ
Anticancer Res; 2004; 24(3a):1805-11. PubMed ID: 15274359
[TBL] [Abstract][Full Text] [Related]
34. Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy.
Anderson JC; Swede H; Rustagi T; Protiva P; Pleau D; Brenner BM; Rajan TV; Heinen CD; Levine JB; Rosenberg DW
Cancer Causes Control; 2012 Feb; 23(2):355-61. PubMed ID: 22187142
[TBL] [Abstract][Full Text] [Related]
35. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.
Hurlstone DP; Karajeh M; Sanders DS; Drew SK; Cross SS
Am J Gastroenterol; 2005 Jun; 100(6):1283-9. PubMed ID: 15929758
[TBL] [Abstract][Full Text] [Related]
36. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.
Giardiello FM; Hamilton SR; Krush AJ; Piantadosi S; Hylind LM; Celano P; Booker SV; Robinson CR; Offerhaus GJ
N Engl J Med; 1993 May; 328(18):1313-6. PubMed ID: 8385741
[TBL] [Abstract][Full Text] [Related]
37. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.
Zell JA; Lin BS; Madson N; McLaren CE; Gerner EW; Meyskens FL
Cancer Causes Control; 2012 Oct; 23(10):1739-44. PubMed ID: 22907422
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic and genotypic characteristics of aberrant crypt foci in human colorectal mucosa.
Nucci MR; Robinson CR; Longo P; Campbell P; Hamilton SR
Hum Pathol; 1997 Dec; 28(12):1396-407. PubMed ID: 9416697
[TBL] [Abstract][Full Text] [Related]
39. Effects of sulindac on sporadic colorectal adenomatous polyps.
Matsuhashi N; Nakajima A; Fukushima Y; Yazaki Y; Oka T
Gut; 1997 Mar; 40(3):344-9. PubMed ID: 9135523
[TBL] [Abstract][Full Text] [Related]
40. Leukotriene Receptor Antagonist Therapy for the Chemoprevention of Human Rectal Aberrant Crypt Foci: Nonrandomized, Open-Label, Controlled Trial.
Higurashi T; Ashikari K; Tamura S; Saigusa Y; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Kessoku T; Hosono K; Yoneda M; Nakajima A
Cancer Prev Res (Phila); 2022 Oct; 15(10):661-668. PubMed ID: 36083855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
